louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06513780: A Study of the Correlation Between Portal Vein Thrombosis and Prognosis of Liver Transplantation
Official title: A Study of the Correlation Between Portal Vein Thrombosis and Prognosis of Liver Transplantation
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Portal Vein Thrombosis
Lead sponsor: Beijing Friendship Hospital
Sponsor class: OTHER
First posted: 2024-07-22
Enrollment: 700
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who underwent in situ liver transplantation at the Liver Transplantation Center of Beijing Friendship Hospital affiliated with Capital Medical University from 2016-1-1 to 2025-12-31

Brief summary: The goal of this observational study is to investigate the correlation between portal vein thrombosis (PVT) and the prognosis of liver transplantation. The main questions it aims to address are:

What is the prevalence of PVT? What are the risk factors associated with PVT? What is the prognostic impact of preoperative PVT on liver transplantation?

Participants are divided into two groups: the PVT group and the non-PVT group. The investigators will comparatively analyze the data of both groups, estimate the prevalence and risk factors of PVT, construct a predictive model for PVT that is applicable in clinical settings, and clarify the prognostic effects of PVT.

Detailed description: The investigators aim to investigate the prevalence and risk factors of PVT, to develop a novel grading or rating system for PVT, and to explore the prognostic impact of preoperative PVT in liver transplantation.

The investigators will:

Recruit patients according to the inclusion/exclusion criteria and obtain signed informed consents. They will collect demographic and laboratory characteristics and classify patients into the PVT group and the non-PVT group based on preoperative ultrasound and/or computed tomography.

Collect patients' perioperative medical imaging, surgical procedures, pathology reports, postoperative treatments, follow-up data, and clinical endpoints.

Comparatively analyze the data of the PVT and non-PVT groups, estimate the prevalence and risk factors of PVT, construct a predictive model for PVT that is applicable in clinical settings, clarify the prognostic effects of PVT, and propose a grading/rating system for PVT.

Eligibility criteria: Inclusion Criteria:

1. Liver transplantation recipients
2. Aged 18 years or older.

Exclusion Criteria:

1. Retransplantation
2. Multi-organ transplantation
3. Portal vein tumor thrombus

Primary outcomes:
measure: Death
timeFrame: 10 years
measure: Postoperative portal vein thrombosis
timeFrame: 10 years
measure: Postoperative portal vein stenosis
timeFrame: 10 years
Secondary outcomes:
measure: Postoperative complications
timeFrame: 1 year
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Friendship Hospital, Capital Medical University
Study officials:
References:
Clinical trial NCT02852980: Estimate Rate of the Women Who Have Gestational Diabetes
Official title: Retrospective Study to Estimate Screening of the Type 2 Diabetes of Women Who Had Childbirth in the Hospital Center Rene Dubos and Having Gestational Diabetes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes, Gestational
Lead sponsor: Hôpital NOVO
Sponsor class: OTHER
First posted: 2016-08-02
Enrollment: 384
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women who had childbirth in the Hospital center Rene Dubos and having gestational diabetes.

Brief summary: Retrospective study to estimate screening of the type 2 diabetes of women who had childbirth in the Hospital center Rene Dubos and having gestational diabetes.

Detailed description: It is recognized that pregnant women who had gestational diabetes (DG) multiplied by 7 subsequent risk of developing type 2 diabetes and this during 25 years. There is at present no formal recommendation of the High Authority for Health (HAS) as an organization of a long term screening for those women. However the recommendations of CNGOF (French Council of Gynaecologists and Obstetricians) and SFD (French society of diabetes) recommend screening for type 2 diabetes after a gestational diabetes in the postnatal consultation. But today how many women views due to a gestational diabetes have realized their screening? It is likely that the rate of occurrence of type 2 diabetes after gestational diabetes is underestimated today. Otherwise it is possible that the occurrence of type 2 diabetes is associated with some risk factors such as high BMI, insulin therapy during pregnancy. Another interrogation is the role of the doctor to reduce the number of women who do not realize their screening at 3 months postpartum. Better awareness of the importance of long term monitoring would reduce the proportion of women who do not realize their screening.

Eligibility criteria: Inclusion Criteria:

* Participants aged over 18 years
* Participants who deliver between 01/01/2013 and 30/06/2015
* Participants who have had a gestational diabetes
* Participants who have been informed and have returned the questionary

Exclusion Criteria:

* Participants who do not wishing to participate in the study

Primary outcomes:
measure: Glycemia realized after childbirth
timeFrame: 3 months
Secondary outcomes:
measure: Percentage of women who have pursued the dietary and hygiene rules
timeFrame: 3 months
Other outcomes:
Locations:
city: Pontoise
country: France
facility: Rene Dubos Hospital
state: Val d'Oise
Study officials:
affiliation: Rene Dubos Hospital
name: Catherine CAMPINOS, PH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00544180: ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week
Official title: Record on Satisfaction of Patients With Actonel 35 mg Once a Week
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Osteoporosis
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
Collaborators: name: Procter and Gamble
First posted: 2007-10-16
Enrollment: 7
Sex: FEMALE
Minimum age (years): 55
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To determine the satisfaction of subject with Actonel 35 mg Once a Week in the treatment of post-menopausal osteoporosis. Open, non-controlled, multi-center study.


Eligibility criteria: Inclusion criteria :

* Postmenopausal ambulatory women
* Established osteoporosis

Exclusion criteria:

* History of cancer: basal cell or squamous cell carcinoma-documented 6-month remission,
* Diagnosis of hypocalcemia, hyperparathyroidism, hyperthyroidism

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Primary outcomes:
measure: Patient satisfaction and compliance
timeFrame: During all the study
Secondary outcomes:
Other outcomes:
Locations:
city: Natanya
country: Israel
facility: Sanofi-Aventis
Study officials:
affiliation: Sanofi
name: Jean-Marc Chantelot, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01034280: Correlations Phenotype / Genotype in Down Syndrome
Official title: Epidemiological Study of Trisomy 21 With Research of Correlations Between Phenotype (Physical, Psychometrical) and Genotype (Genome, Transcriptome, Proteome)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Down Syndrome
Keywords: Down Syndrome
phenotype
genotype
patient family
Lead sponsor: Institut Jerome Lejeune
Sponsor class: OTHER
Collaborators: name: Fondation Jérôme Lejeune
First posted: 2009-12-17
Enrollment: 524
Sex: ALL
Minimum age (years): 8
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: Down syndrome patients

Brief summary: The purpose of this study is to correlate phenotype and genotype of Down syndrome patients in order to identify the biochemical reactions involved in their mental retardation and their other phenotypic characteristics.


Eligibility criteria: Inclusion Criteria:

* Down syndrome patients
* age: 8years and older
* assessment by the psychometric tests
* possible blood tests

Exclusion Criteria:

* no exclusion criteria

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Institut Jerome Lejeune
Study officials:
affiliation: Institut Jerome Lejeune
name: Yann Grattau, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT06032780: Eccentric Resistance Training Among Individuals With Chronic Heart Failure
Official title: Effects of Eccentric Resistance Training on Ventricle Functions and Aerobic Capacity Among Individuals With Chronic Heart Failure
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Heart Failure
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2023-09-13
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: To determine the effects of eccentric resistive training on ventricle functions and aerobic capacity as compared to a resistance and aerobic training among Heart failure (HF)


Eligibility criteria: Inclusion Criteria:

* Patient able to safely perform lower limb exercise will be check by six- minute walk test (6 MWT)
* Diagnosis of Chronic HF and currently on optimal medical therapy

Exclusion Criteria:

* Already participating in cardiac rehabilitation

  * New York Heart Association (NYHA) Classification of HF class IV HF symptoms
  * Co-existent other disease such as asthma/ COPD/interstitial lung disease.
  * Symptomatic Second degree or third degree heart block.
  * ECG with uncontrolled ventricular arrhythmia
  * limited Exercise ability due to neurologic or orthopedic impairments of the legs (will cross-check with 6 MWT)

Primary outcomes:
measure: Ventricle Functions
timeFrame: 12 week
measure: Aerobic Capacity
timeFrame: 12 week
Secondary outcomes:
measure: Quality of life (Minnesota Living with Heart Failure Questionnaire)
timeFrame: 12 week
measure: Strength
timeFrame: 12 week
measure: Maximal strength of respiratory muscles
timeFrame: 12 week
measure: Forced Expiratory Volume in 1 second (FEV1)
timeFrame: 12 week
measure: Forced vital Capacity (FVC)
timeFrame: 12 week
measure: Peak Expiratory Flow (PEF)
timeFrame: 12 week
measure: Cardiac Risk Factors - Blood Pressure
timeFrame: 12 week
measure: Cardiac Risk Factors - Body mass index
timeFrame: 12 week
measure: Cardiac Risk Factors - Lipid profile
timeFrame: 12 week
Other outcomes:
measure: Oxygen Saturation (SpO2)
timeFrame: 12 week
measure: Change in heart rate variability (HRV)
timeFrame: 12 week
measure: Modified Borg Dyspnoea Scale
timeFrame: 12 week
measure: Fatigue Severity Scale (FSS)
timeFrame: 12 week
measure: Adverse events
timeFrame: 12 week
measure: Change in medication
timeFrame: 12 week
measure: Adherence to the program
timeFrame: 12 week
measure: Satisfaction score
timeFrame: 12 week
measure: Thigh circumference
timeFrame: 12 week
Locations:
city: Rawalpindi
country: Pakistan
facility: Pakistan Railway Hospital
state: Punjab
Study officials:
affiliation: Riphah International University
name: Muhammad Iqbal Tariq, PhD*
role: PRINCIPAL_INVESTIGATOR
affiliation: Riphah International University
name: Arshad Nawaz Malik, PhD
role: STUDY_CHAIR
affiliation: University of Notre Dame Australia
name: Shane Patman, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT04873180: Significance of Immunohistochemical Expression of Survivin in Renal Cell Carcinoma
Official title: A Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Renal Cell Carcinoma
Keywords: Renal Cell Carcinoma
Survivin
Immnuohistochemistry
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2021-05-05
Enrollment: 40
Sex: ALL
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with symptoms and signs of renal neoplasms admitted to Sohag University hospital and underwent nephrectomy operations. excisional specimens sent to pathology Lab will be sectioned and stained by H\&E. only cases of renal cell carcinoma will be included in the study.

Brief summary: detection of Survivin expression in renal cell carcinoma and correlate this expression to tumor grade and stage.

Detailed description: renal cell carcinoma is the third most prevalent malignant tumor of the genitourinary system. deregulation of apoptosis is involved in carcinogenesis by abnormally prolonged cell survival, facilitating accumulations of multiple mutations and augment resistance to immune-surveillance. Survivin is a member of inhibitor of Apoptosis Protein family (IAPs). it play a role in cell cycle regulation by inhibiting apiptosis. Survivin is over-expressed in many human neoplasms.

Eligibility criteria: Inclusion Criteria:

* patients suffer from renal cell carcinomas

Exclusion Criteria:

* patients received pre-operative chemotherapy or radiotherapy. patients with insufficient clinical data.

Primary outcomes:
measure: expression of survivin in neoplastic and adjacent normal renal tissues
timeFrame: april, 2021
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Maisa Hashem Mohammed
Study officials:
affiliation: a lecturer of pathology, Sohag faculty of medicine
name: Maisa H Mohammed, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04884880: Efficacy and Safety of Luo-Fu-Shan Plaster in Patients With Rheumatoid Arthritis
Official title: Prospective, Multicentre, Randomized, Double-blind, Placebo-controlled Clinical Trial of Luo-Fu-Shan Plaster in the Treatment of Rheumatoid Arthritis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Arthritis, Rheumatoid
Keywords: Rheumatoid Arthritis
External therapy
Herb medicine
Lead sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Sponsor class: OTHER
First posted: 2021-05-13
Enrollment: 180
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: 180 subjects will be randomized to two parallel groups (90 subjects per group) to receive Luo-Fu-Shan Plaster 10g once daily. Placebo will be administered to individuals randomized to that treatment group in a form identical to the Luo-Fu-Shan Plaster. The first investigational medicinal product dose will be administered the day after the randomization.
Primary purpose: TREATMENT

Brief summary: The aim of this study is to assess the efficacy and safety of Luo-Fu-Shan Plaster in patients with Rheumatoid Arthritis.

Detailed description: The investigators are inspired by Chinese traditonal herb, an therapy for thousands of years, and take its advantage to make Luo-Fu-Shan Plaster in order to get an effective and safe treatment for active RA patients. The study is a multicenter, randomized, double-blind, placebo-controlled trial.

Eligibility criteria: Inclusion Criteria:

* Male or female subjects aged 18 to 75 years (time of get informed consent)
* Documented diagnosis of rheumatoid arthritis, as defined by the American Rheumatism Association 1987 Revised Criteria.
* Documented diagnosis of damp-heat syndrome according to Traditional Chinese Medicine.
* If patients are receiving Disease-modifying anti-rheumatic drugs (DMARDs), then the doses should have been kept stable for at least 12 weeks.
* If patients are receiving non-steroidal anti-inflammatory drugs (NSAIDs) or orally Chinese herbal medicine, then the doses should have been kept stable for at least 4 weeks.

Exclusion Criteria:

* Skin allergies or broken skin;
* Taking glucocorticoids,more than 10 mg daily.
* Female patients who are pregnant, breast-feeding or planed to be pregnant;

Primary outcomes:
measure: The changes of Visual Analogue Scale(VAS) pain score
timeFrame: Day 1 to Week 4
Secondary outcomes:
measure: The changes of the Disease Activiyu Score (DAS28)
timeFrame: Day 1 to Week 4
Other outcomes:
measure: The score of the Health Assessment Questionnaire (HAQ-DI)
timeFrame: Day1 to Week 4
measure: The score of the RA-PRO
timeFrame: Day 1 to Week 4
Locations:
city: Beijing
country: China
facility: Guang'anmen Hospital of China Academy of Chinese Medical Sciences
state: Beijing
Study officials:
affiliation: Guang'anmen Hospital
name: Jiang Quan, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01382680: Comparison of the Guide-wire G-240 to a Combination of a Flexible/Hydrophil and a Nitinol Guide Wire
Official title: Comparison of the Use of the Guide-wire G-240 to a Combination of a Flexible/Hydrophil Guide Wire With a Nitinol Wire in Patients With Stenosis of the Bile Ducts in ERCP
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Other Specified Diseases of Biliary Tract
Lead sponsor: Johann Wolfgang Goethe University Hospital
Sponsor class: OTHER
First posted: 2011-06-27
Enrollment: 222
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: In ERCP practice, most often a combined use of guidewires is necessary to attain a therapeutic aim. E.g. a hyperflexible hydrophilic guidewire is changed after cannulating a stricture to a nitinol wire for improved stability with the use of therapeutic devices. A new guide-wire (G240) combines these characteristics with a stable shaft and a hydrophilic tip. The investigators test the hypothesis that the use of this new guidewire would decrease number of guidewires used within one ERCP session.

Detailed description: This is a randomized, monocentric study.

Eligibility criteria: Inclusion Criteria:

* Obstruction of the biliary tract (cross sectional imaging or ultrasonography/lab data)

Exclusion Criteria:

* Operatively alternated anatomy of the patient.
* Intervention of the pancreatic duct.

Primary outcomes:
measure: Number of guidewires per ERCP session
timeFrame: Within the same ERCP session (day 1)
Secondary outcomes:
measure: Treatment aim
timeFrame: day 1
measure: Time of ERCP session
timeFrame: day 1
Other outcomes:
Locations:
city: Frankfurt
country: Germany
facility: Department of Internal Medicine I
Study officials:
affiliation: Johann Wolfgang Goethe University Hospital and Clinics Department of Internal Medicine I
name: Jörg G Albert, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Albert JG, Lucas K, Filmann N, Herrmann E, Schroder O, Sarrazin C, Trojan J, Kronenberger B, Bojunga J, Zeuzem S, Friedrich-Rust M. A novel, stiff-shaft, flexible-tip guidewire for cannulation of biliary stricture during endoscopic retrograde cholangiopancreatography: a randomized trial. Endoscopy. 2014 Oct;46(10):857-61. doi: 10.1055/s-0034-1377628. Epub 2014 Sep 10.
Clinical trial NCT00459680: Acupuncture and Laser Acupoint Treatment on Hypertension
Official title: Acupuncture and Laser Acupoint Treatment on Hypertension
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Hypertension
Keywords: hypertension
acupuncture
laser
Lead sponsor: Logan College of Chiropractic
Sponsor class: OTHER
First posted: 2007-04-12
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To determine the effect of acupuncture and laser acupuncture point treatment on hypertensive subjects.

Detailed description: The specific aims of the study are to test the effectiveness of acupuncture and laser acupoint on hypertension. The hypothesis is: the stimulation of a pattern of acupoints with acupuncture and laser will result in significant reductions in blood pressure. The points that are going to be used for the study are: Zusanli (St36), Tianshu (St25), Quchi (LI11).

Eligibility criteria: Inclusion Criteria:

* Male or female over 18 and under 70 years of age with hypertension (blood pressure over 140/90 mmhg).

Exclusion Criteria:

* Individuals with heart, kidney, thyroid disorders, diabetes, chronic disease or illness, neurological diseases, skin or bleeding disorders, and currently taking drugs or medications will not be recruited in the study. A health history questionnaire will be used to screen the subjects.

Primary outcomes:
measure: Blood pressure
timeFrame: Pretreatment then at 2 and 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Chesterfield
country: United States
facility: Logan College of Chiropractic
state: Missouri
Study officials:
affiliation: Logan College of Chiropractic
name: John Zhang, MD. PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04684862: Infusion System for Hepatic Cancer
Official title: Combined Infusion System to Deliver Chemotherapy Regionally to the Liver
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Colorectal Cancer Metastatic to Liver
Intrahepatic Cholangiocarcinoma
Lead sponsor: Abramson Cancer Center at Penn Medicine
Sponsor class: OTHER
First posted: 2020-12-28
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a single-site, open-label continued access study/treatment protocol under a treatment IDE. In addition to treating patients, the primary objective of this study is to assess the safety of using the Medtronic SynchroMed II programmable pump combined with the Intera tapered catheter for hepatic artery infusion (HAI) of a standard chemotherapy (FUDR) drug for adults with a clinical or biopsy-proven diagnosis of colorectal cancer metastatic to the liver or intrahepatic cholangiocarcinoma.

After successful implantation, the combined pump and catheter system will be evaluated using a nuclear scan in the postoperative period, which is standard procedure to confirm that the pump is functioning prior to HAI of FUDR. Monitoring for safety will include a record of residual pump volume when it is emptied (every 2-12 weeks depending on whether the pump is being used for chemotherapy infusion) to determine if the pump is still working and surveillance of routine cross-sectional imaging (usually every 2-6 months) for any sign of a pump or catheter problem. Patients will be monitored for the safety of the pump/catheter combination for up to 5 years or pump removal/study withdrawal.


Eligibility criteria: Inclusion Criteria:

* Patients must be greater than or equal to 18 years of age
* Have a clinical or biopsy-proven diagnosis of colorectal cancer metastatic to liver or intrahepatic cholangiocarcinoma
* At the time of pump placement, patients will either have unresectable, chemotherapy-responsive disease or they will be undergoing resection with planned postoperative HAI
* Be deemed appropriate for pump chemotherapy by both a medical oncologist and a surgical oncologist
* Provision of signed and dated informed consent form

Exclusion Criteria:

* Known active infection
* Is pregnant or breastfeeding or expecting to conceive children within the projected duration of the trial

Primary outcomes:
measure: Number of Targeted Adverse Events (TAEs)
timeFrame: From surgery up to 60 months post-surgery or study withdrawal
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Hospital of the University of Pennsylvania
state: Pennsylvania
Study officials:
References: